|
1
|
Scheithauer BW, Gaffey TA, Lloyd RV, Sebo
TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki
T, et al: Pathobiology of pituitary adenomas and carcinomas.
Neurosurgery. 59:341–353. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Korbonits M and Carlsen E: Recent clinical
and pathophysiological advances in non-functioning pituitary
adenomas. Horm Res. 71(Suppl 2): 123–130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saeger W, Lüdecke DK, Buchfelder M,
Fahlbusch R, Quabbe HJ and Petersenn S: Pathohistological
classification of pituitary tumors: 10 years of experience with the
German Pituitary Tumor Registry. Eur J Endocrinol. 156:203–216.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colao A, Pivonello R, Di Somma C,
Savastano S, Grasso LF and Lombardi G: Medical therapy of pituitary
adenomas: Effects on tumor shrinkage. Rev Endocr Metab Disord.
10:111–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chand-Fouché ME, Colin P and Bondiau PY:
Pituitary adenomas: Multimodal management and modern irradiation
techniques. Cancer Radiother. 16(Suppl): S90–S100. 2012.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grossman AB: The 2004 World Health
Organization classification of pituitary tumors: Is it clinically
helpful? Acta Neuropathol. 111:76–77. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gürlek A, Karavitaki N, Ansorge O and Wass
JA: What are the markers of aggressiveness in prolactinomas?
Changes in cell biology, extracellular matrix components,
angiogenesis and genetics. Eur J Endocrinol. 156:143–153. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wierinckx A, Auger C, Devauchelle P,
Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C,
Figarella-Branger D, et al: A diagnostic marker set for invasion,
proliferation, and aggressiveness of prolactin pituitary tumors.
Endocr Relat Cancer. 14:887–900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Shraim M and Asa SL: The 2004 World
Health Organization classification of pituitary tumors: What is
new? Acta Neuropathol. 111:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herr P, Hausmann G and Basler K: WNT
secretion and signalling in human disease. Trends Mol Med.
18:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saito-Diaz K, Chen TW, Wang X, Thorne CA,
Wallace HA, Page-McCaw A and Lee E: The way Wnt works: Components
and mechanism. Growth Factors. 31:1–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Polakis P: The many ways of Wnt in cancer.
Curr Opin Genet Dev. 17:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polakis P: Wnt signaling in cancer. Cold
Spring Harb Perspect Biol. 4:pii.a0080522012. View Article : Google Scholar
|
|
16
|
Cruciat CM and Niehrs C: Secreted and
transmembrane wnt inhibitors and activators. Cold Spring Harb
Perspect Biol. 5:a0150812013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hrzenjak A, Tippl M, Kremser ML,
Strohmeier B, Guelly C, Neumeister D, Lax S, Moinfar F, Tabrizi AD,
Isadi-Moud N, et al: Inverse correlation of secreted
frizzled-related protein 4 and beta-catenin expression in
endometrial stromal sarcomas. J Pathol. 204:19–27. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O'Hurley G, Perry AS, O'Grady A, Loftus B,
Smyth P, O'Leary JJ, Sheils O, Fitzpatrick JM, Hewitt SM, Lawler M
and Kay EW: The role of secreted frizzled-related protein 2
expression in prostate cancer. Histopathology. 59:1240–1248. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saran U, Arfuso F, Zeps N and Dharmarajan
A: Secreted frizzled-related protein 4 expression is positively
associated with responsiveness to cisplatin of ovarian cancer cell
lines in vitro and with lower tumour grade in mucinous ovarian
cancers. BMC Cell Biol. 13:252012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marsit CJ, Karagas MR, Andrew A, Liu M,
Danaee H, Schned AR, Nelson HH and Kelsey KT: Epigenetic
inactivation of SFRP genes and TP53 alteration act jointly as
markers of invasive bladder cancer. Cancer Res. 65:7081–7085. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qi J, Zhu YQ, Luo J and Tao WH:
Hypermethylation and expression regulation of secreted
frizzled-related protein genes in colorectal tumor. World J
Gastroenterol. 12:7113–7117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chung MT, Lai HC, Sytwu HK, Yan MD, Shih
YL, Chang CC, Yu MH, Liu HS, Chu DW and Lin YW: SFRP1 and SFRP2
suppress the transformation and invasion abilities of cervical
cancer cells through Wnt signal pathway. Gynecol Oncol.
112:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vézina JL, Hardy J and Yamashita M:
Microadenomas and hypersecreting pituitary adenomas. Arq
Neuropsiquiatr. 33:119–127. 1975.(In Portuguese). PubMed/NCBI
|
|
24
|
Knosp E, Steiner E, Kitz K and Matula C:
Pituitary adenomas with invasion of the cavernous sinus space: A
magnetic resonance imaging classification compared with surgical
findings. Neurosurgery. 33:610–618. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zlobec I, Terracciano L, Jass JR and Lugli
A: Value of staining intensity in the interpretation of
immunohistochemistry for tumor markers in colorectal cancer.
Virchows Arch. 451:763–769. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao P, Wang H, Gao H, Li C and Zhang Y:
Reversal of multidrug resistance by magnetic chitosan-Fe3O4
nanoparticle-encapsulated MDR1 siRNA in glioblastoma cell line.
Neurol Res. 35:821–828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu R, Zhong J, Li M, Guo X, Zhang H and
Chen J: PACAP induces the dimerization of PAC1 on the nucleus
associated with the cAMP increase in the nucleus. Neurosci Lett.
549:92–96. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuster DW, Merkus D, Jorna HJ, Dekkers DH,
Duncker DJ and Verhoeven AJ: Nuclear protein extraction from frozen
porcine myocardium. J Physiol Biochem. 67:165–173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sano M, Driscoll DR, De Jesus-Monge WE,
Klimstra DS and Lewis BC: Activated wnt signaling in stroma
contributes to development of pancreatic mucinous cystic neoplasms.
Gastroenterology. 146:257–267. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Morris JP IV, Yan W, Schofield
HK, Gurney A, Simeone DM, Millar SE, Hoey T, Hebrok M and di Pasca
Magliano M: Canonical wnt signaling is required for pancreatic
carcinogenesis. Cancer Res. 73:4909–4922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chambers TJ, Giles A, Brabant G and Davis
JR: Wnt signalling in pituitary development and tumorigenesis.
Endocr Relat Cancer. 20:R101–R111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Q, Shen K, Zhao Y, He X, Ma C, Wang L,
Wang B, Liu J and Ma J: MicroRNA-222 promotes tumorigenesis via
targeting DKK2 and activating the Wnt/β-catenin signaling pathway.
FEBS Lett. 587:1742–1748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dellinger TH, Planutis K, Tewari KS and
Holcombe RF: Role of canonical Wnt signaling in endometrial
carcinogenesis. Expert Rev Anticancer Ther. 12:51–62. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC,
Wang C and Hong YR: Differential expression of Wnt genes,
beta-catenin and E-cadherin in human brain tumors. Cancer Lett.
183:95–101. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Elston MS, Gill AJ, Conaglen JV, Clarkson
A, Shaw JM, Law AJ, Cook RJ, Little NS, Clifton-Bligh RJ, Robinson
BG and McDonald KL: Wnt pathway inhibitors are strongly
down-regulated in pituitary tumors. Endocrinology. 149:1235–1242.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng YY, Yu J, Wong YP, Man EP, To KF,
Jin VX, Li J, Tao Q, Sung JJ, Chan FK and Leung WK: Frequent
epigenetic inactivation of secreted frizzled-related protein 2
(SFRP2) by promoter methylation in human gastric cancer. Br J
Cancer. 97:895–901. 2007.PubMed/NCBI
|
|
38
|
Becker G, Kocher M, Kortmann RD, Paulsen
F, Jeremic B, Müller RP and Bamberg M: Radiation therapy in the
multimodal treatment approach of pituitary adenoma. Strahlenther
Onkol. 178:173–186. 2002. View Article : Google Scholar : PubMed/NCBI
|
